Development Of Prognostic And Predictive Biomarkers To Aid Treatment Of Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
Although a number of new therapies are emerging in the treatment of lung cancer, chemotherapy remains the backbone of treatment for most patients. Currently we are unable to predict who will benefit from chemotherapy with some patients deriving no benefit but experiencing significant toxicity. Our group has investigated a number of biomarkers and found them to predict response to chemotherapy. These markers may be used to determine patients most likely to derive benefit from chemotherapy.
The Role Of The Acute Phase Response In Docetaxel Resistance In Hormone-refractory Prostate Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$74,365.00
Summary
Prostate cancer is the most common cancer in Australian men. Chemotherapy is used in advanced disease, but is only effective in ~50% of patients. In the first year of my PhD, I identified 8 plasma biomarkers that predict chemotherapy resistance. I plan to characterise how these immune molecules cause chemotherapy resistance using a mouse model of advanced prostate cancer. These markers may allow us to personalise prostate cancer treatment in the future and identify more effective therapies.